Making Sense of Merkel Cell Carcinoma


NeuroEndocrine Cancer Australia invites people affected by Merkel Cell Carcinoma, families and friends, and interested health professionals to our free online forum. Join guest experts in discovering the latest developments in Merkel Cell Carcinomas and optimal pathway for treatment.

The Speakers

Richard Tothill

Dr Tothill is a research scientist and head of the Rare Disease Oncogenomics Laboratory within Department of Clinical Pathology at the University of Melbourne. Since 2001 he has established a career in the field of cancer genomics. His work has been highly translational with a focus on the adoption of breakthrough genomic technologies for discovery and clinical applications. He currently leads collaborative research and national clinical studies on rare diseases including cancers of unknown primary, Merkel cell carcinoma and other neuroendocrine malignancies.

Gerald Fogarty

Professor Gerald B. Fogarty FRANZCR, PhD is Director of Radiation Oncology at Mater Hospital, Sydney. He trained at Peter MacCallum Cancer Centre. He is a radiation oncologist with Melanoma Institute of Australia. Professor Fogarty authored the radiotherapy section of the 2019 NHMRC Management of Keratinocyte Guidelines. He is a board member of the Melanoma and Skin Cancer Trials Group and Chair of the Australian Merkel Interest Group. His career goal is to establish level one evidence for radiation in skin cancer. He is currently the Master of Warrane College, an affiliated residential College at UNSW.

Dr Wen Xu

Dr Wen Xu is a staff specialist medical oncologist based at the Princess Alexandra Hospital in Brisbane who specialises in breast, lung and skin cancers, with a particular interest in Merkel Cell Carcinoma. He has previously undertaken a melanoma and immuno-oncology fellowship at the Peter MacCallum Cancer centre in 2016; as well as a Phase I Drug Development fellowship at the Royal Marsden in 2017, before returning to Brisbane in 2018. He is CIA of the MRFF funded I-MAT trial (Adjuvant Avelumab in Merkel cell carcinoma trial).

When: Thursday 5th November

Time: 5pm – 7:15pm


5:00pm – 5.10pm

Welcome & Introductions

5.10pm – 5.30pm

What it is & Medical Oncology management – Dr Wen Xu

5.30pm – 5.55pm
Pathways & Radiation Therapy – Prof Gerald Fogarty

5.55pm – 6.20pm
Genomics – Dr Richard Tothill

6.20pm – 6.35pm
Patient Experience – Jonathan Pincus

6.35pm – 6.50pm
Support Services

6.50pm – 7.10pm

7.10pm – 7.15pm